Vulvovaginal Candidiasis
3
Pipeline Programs
1
Companies
4
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
ScynexisJERSEY CITY, NJ
4 programs1
1
1
IbrexafungerpPhase 31 trial
SCY-078Phase 21 trial
IbrexafungerpPhase 11 trial
Non-interventional studyN/A1 trial
Active Trials
+1 more trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
ScynexisIbrexafungerp
ScynexisSCY-078
ScynexisIbrexafungerp
ScynexisNon-interventional study
Clinical Trials (4)
Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis
Start: May 2022Est. completion: Aug 2023
Phase 3Completed
Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis
Start: Nov 2015Est. completion: Aug 2016
Phase 2Completed
Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp
Start: Jul 2023Est. completion: Nov 2023
Phase 1Completed
Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant Outcomes
Start: Jul 2022Est. completion: Oct 2029
N/ARecruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials
1 companies competing in this space